ORTHO Regenerative Technologies $ORTH.ca $ORTIF is Using Proprietary Tech to Improve Surgery Success Rates and Seize a $5bn Market Opportunity

ORTHO Regenerative Technologies is a cutting-edge med tech firm that  uses its proprietary RESTORE technology platform to dramatically improve  the success rate of orthopedic and sports medicine surgeries. In layman’s terms, that means company has a wonder delivery platform  that delivers biologics – drugs made from biological processes – to  repair soft tissues in the human body. The technology uses biologics derived from things like plasma and  bone marrow concentrate to regenerate new tissue in various  musculoskeletal conditions. This includes Wound Healing, Cartilage repair and Osteo-arthritis So, how big is the market opportunity for Soft Tissue Repair? At least $5bn in the U.S. alone. This includes: Rotator Cuff TEAR (which leads to shoulder dysfunction and pain): 4m patients in the U.S. alone 600,000 annual surgeries in the U.S. alone $600m+ market opportunity Meniscus Tear Repair (which is painful and compromises knee function): There are 1.2m surgeries annually in U.S. alone $1bn+ market opportunity Cartilage Lesions Repair (this is where lesions cause friction and pain): 1.2m detected lesions annually in U.S. alone 120,000 surgeries and a lack of options $1bn+ market opportunity Get comfy for this insightful interview with Claude LeDuc, Ortho’s CEO.